4 Marijuana Stocks Looking To Pick Up Speed This Month

CORAL GABLES, FL / ACCESSWIRE / February 8, 2019 / Marijuana stocks have become one of the hottest topics in the news over the course of the past few years. Recently, the cannabis industry has seen an increase in capital enjoyed by companies working to optimize and innovate products for the adult-use recreational cannabis market. As it relates to positive legislation brought forth by lawmakers, as many as 33 states in the U.S. have passed laws allowing for the use of cannabis, with many of those offering recreational cannabis as well. It's clear that the majority of the country is in favor of legalizing cannabis, and as this data continues to grow, so does the market. With the increase of capital and business entering the market, the cannabis sector has shown exciting promise in terms of opportunities for investors looking to the space. Global Consortium Inc (OTC:GCGX), American Cannabis Company Inc (OTC PINK: AMMJ), GW Pharmaceuticals plc (GWPH), and INSYS Therapeutics Inc (INSY) are four pot stocks looking to pick up speed this month.

Global Consortium Inc (OTC:GCGX) that you might not have heard of, but could benefit from keeping on your radar in the coming months, Global Consortium is putting in the work to become one of the industry leaders in terms of hemp-derived CBD products, and the market has responded favorably to these strategic moves. While other companies in the sector have become distracted, Global Consortium has maintained a focus that not only targets corporate growth but also tackles the public markets as well.

As the Company takes the steps necessary to lead the CBD industry into the future, Global Consortium Inc (OTC:GCGX) has made it a point to build a corporate framework for these aspirations to be built upon. The Company announced plans earlier this week to design and build out America's first "Cannabis Mall." Per the details of the announcement, the Cannabis Mall, when completed, will house manufacturing, distribution, delivery, retail, and cultivation all under one 64,000 sure foot building.

In more recent news, Global Consortium Inc (OTC:GCGX) announced on Tuesday that it has entered into a Letter of Intent with MJ Munchies, Inc whereby Global Consortium subsidiary Infused Edibles would receive an exclusive license to manufacture and distribute marijuana and CBD-infused products under the Half-Bakedâ„¢ mark owned by MJ Munchies.

For More Information On Global Consortium Inc, Click Here

American Cannabis Company Inc (AMMJ), a full-service B2B consulting solutions provider, and seller of ancillary products to the cannabis industry announced just before the new year, that the Company had filed its Form 10-K for the year ended December 31, 2017, with the Securities and Exchange Commission.

Following this announcement, Terry Buffalo, the Company's Principal Executive Officer, commented, "I am happy to announce this filing. The Company ran into significant headwinds that caused it to be late with its annual report for last year, including the death of our CFO's wife at the start of the audit process, and the resulting difficulties caused by our auditor not having conducted a previous audit of our Company. Additionally, we transitioned our Chief Financial Officer's function so that he would work solely for the Company as an employee on-site."

For More Information On American Cannabis Company Inc, Click Here

GW Pharmaceuticals plc (GWPH), a biopharmaceutical company focused on discovering, developing, and commercializing novel therapeutics from its proprietary cannabinoid platform, announced this week that the Company will soon release its financial results for the quarter ending December 31, 2018.

Per the details of the announcement, the Company said they are currently in a transitionary period as they shift to the new fiscal year. GW will also host a conference call the same day at 4:30 p.m. EST. Conference call information will be provided in the financial results press release.

For More Information On GW Pharmaceutical plc, Click Here

INSYS Therapeutics Inc (INSY), a leader in the development, manufacturing, and commercialization of pharmaceutical cannabinoids, today announced the results of a dose-finding pharmacokinetic (PK) study (INS015-18-124) of its epinephrine nasal spray. These results identified a dose that showed a PK profile similar to that of intramuscular injection of EpiPen® (0.3 mg) and Adrenalin® (0.5 mg), both of which are treatments for anaphylaxis, an acute, life-threatening allergic reaction.